Literature DB >> 10499174

Axonal pathology in multiple sclerosis: relationship to neurologic disability.

B D Trapp1, R Ransohoff, R Rudick.   

Abstract

In this review, data is summarized supporting the hypothesis that axonal loss is a major pathologic process responsible for irreversible neurologic disability in patients with multiple sclerosis. Pathologic studies implicate inflammatory demyelination as a principal cause of axonal transection and subsequent axonal degeneration. Axonal degeneration caused by chronic demyelination in the absence of active inflammation may also contribute to progressive disability in the later stages of the disease. Studies using magnetic resonance spectroscopy suggest that axonal loss begins at the onset of the disease, and studies using magnetic resonance imaging have documented brain atrophy in the earliest stages of multiple sclerosis. Brain atrophy increases during the relapsing-remitting disease stage without concurrent disability progression. This suggests that compensatory mechanisms maintain neurologic function, despite progressive brain tissue loss during the early stages of the disease. Beyond a threshold, however, further axonal loss leads to continuously progressive neurologic disability. We hypothesize that the rate and extent of axonal loss during relapsing-remitting multiple sclerosis determines when a patient enters the secondary progressive stage of the disease. This view of disease pathogenesis has several important implications. First, surrogate markers of axonal loss are needed to monitor the disease process for patient care and for clinical trials. We propose brain parenchymal fraction, a precise measure of whole-brain atrophy, as an attractive candidate for this purpose. Second, disease-modifying therapy should be used early in multiple sclerosis patients, before extensive axonal loss has occurred. Third, neuroprotective drugs should be tested in combination with anti-inflammatory drugs in multiple sclerosis patients. Finally, studies of the time course of axonal loss, and its mechanisms are critical for effective therapeutic intervention.

Entities:  

Mesh:

Year:  1999        PMID: 10499174     DOI: 10.1097/00019052-199906000-00008

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  117 in total

1.  Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load, axonal loss, and neurological dysfunction in a murine model of multiple sclerosis.

Authors:  S Sathornsumetee; D B McGavern; D R Ure; M Rodriguez
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  Early-stage multiple sclerosis : what are the treatment options?

Authors:  Per Soelberg Sorensen
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Brain volume and diffusion markers as predictors of disability and short-term disease evolution in multiple sclerosis.

Authors:  P G Sämann; M Knop; E Golgor; S Messler; M Czisch; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

4.  Subventricular zone microglia transcriptional networks.

Authors:  Sarah C Starossom; Jaime Imitola; Yue Wang; Li Cao; Samia J Khoury
Journal:  Brain Behav Immun       Date:  2010-11-11       Impact factor: 7.217

Review 5.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

6.  Multiple sclerosis-related white matter microstructural change alters the BOLD hemodynamic response.

Authors:  Nicholas A Hubbard; Monroe Turner; Joanna L Hutchison; Austin Ouyang; Jeremy Strain; Larry Oasay; Saranya Sundaram; Scott Davis; Gina Remington; Ryan Brigante; Hao Huang; John Hart; Teresa Frohman; Elliot Frohman; Bharat B Biswal; Bart Rypma
Journal:  J Cereb Blood Flow Metab       Date:  2015-11-09       Impact factor: 6.200

7.  Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients.

Authors:  Sarah A Imam; Mary K Guyton; Azizul Haque; Arthur Vandenbark; William R Tyor; Swapan K Ray; Naren L Banik
Journal:  J Neuroimmunol       Date:  2007-09-04       Impact factor: 3.478

Review 8.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

9.  Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.

Authors:  H Li; S H Li; Z X Yu; P Shelbourne; X J Li
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

10.  Corticomotor organisation and motor function in multiple sclerosis.

Authors:  Gary W Thickbroom; Michelle L Byrnes; Sarah A Archer; Allan G Kermode; Frank L Mastaglia
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.